Trials / Not Yet Recruiting
Not Yet RecruitingNCT07429162
Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection
DP-QB-MYA-002 Phage Cocktail for Chronic Multidrug-Resistant (MDR) Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (estimated)
- Sponsor
- Alberta Health services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate mycobacteriophage therapy using in-vitro validated mycobacteriophage DP-QB-MYA-002 in combination with conventional antimycobacterial agents for the treatment of multidrug-resistant Mycobacterium abscessus pulmonary disease, with the goal of reducing mycobacterial burden and improving pulmonary outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DP-QB-MYA-002 | In-vitro effective Mycobacteriophage DP-QB-MYA-002 against specific strain of Mycobacterium abscessus ssp abscessuss |
Timeline
- Start date
- 2026-07-02
- Primary completion
- 2027-07-02
- Completion
- 2028-07-02
- First posted
- 2026-02-24
- Last updated
- 2026-02-24
Source: ClinicalTrials.gov record NCT07429162. Inclusion in this directory is not an endorsement.